REFERENCES

1. Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin Oncol 2009;36:6-7.

2. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8589.00.pdf [Last accessed on 24 Jun 2022].

3. Jiang J, Ren Y, Xu C, Lin X. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report. Diagn Pathol 2022;17:4.

4. McEvoy CR, Fox SB, Prall OWJ. Emerging entities in NUTM1-rearranged neoplasms. Genes Chromosomes Cancer 2020;59:375-85.

5. Kim YH, Song Y, Kim JK, et al. False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases. PLoS One 2019;14:e0222535.

6. Kubonishi I, Takehara N, Iwata J, et al. Novel t(15;19) chromosome abnormality in a thymic carcinoma. Cancer Res 1991;51:3327-8.

7. Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012;18:5773-9.

8. Chau NG, Ma C, Danga K, et al. An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 2020;4:pkz094.

9. Available from: https://nmcregistry.org/ [Last accessed on 24 Jun 2022].

10. Huang QW, He LJ, Zheng S, Liu T, Peng BN. An overview of molecular mechanism, clinicopathological factors, and treatment in nut carcinoma. Biomed Res Int 2019;2019:1018439.

11. Prall OWJ, Thio N, Yerneni S, Kumar B, McEvoy CR. A NUT carcinoma lacking squamous differentiation and expressing TTF1. Pathology 2021;53:663-6.

12. Brägelmann J, Dammert MA, Dietlein F, et al. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Rep 2017;20:2833-45.

13. Han X, Piao L, Zhuang Q, Yuan X, Liu Z, He X. The role of histone lysine methyltransferase NSD3 in cancer. Onco Targets Ther 2018;11:3847-52.

14. Agaimy A, Tögel L, Stoehr R, et al. NSD3-NUTM1-rearranged carcinoma of the median neck/thyroid bed developing after recent thyroidectomy for sclerosing mucoepidermoid carcinoma with eosinophilia: report of an extraordinary case. Virchows Arch 2021;479:1095-9.

15. Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126:1052-66.

16. Zhou J, Duan M, Jiao Q, et al. Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive. IGKV ;11:778296.

17. Allison DB, Rueckert J, Cornea V, Lee CY, Dueber J, Bocklage T. Thyroid carcinoma with NSD3::NUTM1 fusion: a case with thyrocyte differentiation and colloid production. Endocr Pathol 2022;33:315-26.

18. Chau NG, Hurwitz S, Mitchell CM, et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer 2016;122:3632-40.

19. Lim SL, Xu L, Han BC, Shyamsunder P, Chng WJ, Koeffler HP. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. PLoS One 2020;15:e0232068.

20. Jung M, Kim S, Lee JK, et al. Clinicopathological and preclinical findings of NUT carcinoma: a multicenter study. Oncologist 2019;24:e740-8.

21. Zhao C, Dong H, Xu Q, Zhang Y. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opin Ther Pat 2020;30:263-74.

22. Shiota H, Alekseyenko AA, Wang ZA, et al. Chemical screen identifies diverse and novel histone deacetylase inhibitors as repressors of NUT function: implications for NUT carcinoma pathogenesis and treatment. Mol Cancer Res 2021;19:1818-30.

23. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012;7:247-65.

24. Napolitano M, Venturelli M, Molinaro E, Toss A. NUT midline carcinoma of the head and neck: current perspectives. Onco Targets Ther 2019;12:3235-44.

25. Grayson AR, Walsh EM, Cameron MJ, et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene 2013;33:1736-42.

26. Piha-Paul SA, Hann CL, French CA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr 2020;4:pkz093.

27. Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol 2018;36:3007-14.

28. Stathis A, Zucca E, Bekradda M, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov 2016;6:492-500.

29. Liao S, Maertens O, Cichowski K, Elledge SJ. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is. Genes Dev 2018;32:1188-200.

30. Hogg SJ, Vervoort SJ, Deswal S, et al. BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1. Cell Rep 2017;18:2162-74.

31. Xie XH, Wang LQ, Qin YY, et al. Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma. Orphanet J Rare Dis 2020;15:183.